Skip to main content

VolitionRx, Gyros Protein Technologies Win Eurostar Grants for Lung Cancer Dx

NEW YORK — VolitionRx and Gyros Protein Technologies said on Thursday that they have been awarded a combined €946,000 ($1.0 million) in Eurostars grant funding to develop a blood-based lung cancer assay.

Belgium-based VolitionRx received €740,000 in Eurostars funding, whole Uppsala, Sweden-based Gyros, which was recently acquired by Mesa Laboratories, received €206,000.

According to the companies, they will develop 12 liquid biopsy assays designed to differentiate lung cancer from benign disease in patients testing positive in low-dose computerized tomography screens, with the goal of advancing a validated triage panel into regulatory trials. 

The assays will combine VolitionRx's NuQ immunoassays, which are designed to identify and quantify nucleosome structural features such as histone modifications and DNA methylation patterns, with Gyros' Gyrolab automated immunoassay technology.